Cytokine-Enhanced CAR T Cell Therapy Achieves Breakthrough Results in Lymphoma

Penn researchers report 81% response rates and durable remissions in refractory B-cell lymphoma using huCART19-IL18, a next-generation CAR T therapy with a rapid manufacturing process.